Post-transplantation diabetes mellitus in patients with kidney allotransplantation


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To identify the prevalence and risk factors for the development of post-transplantation diabetes mellitus (PTDM) after kidney allotransplantation (Kat). Material and methods. A retrospective analysis of out-patient medical records of 146 kidney allograft recipients, obtained from 1989 to 2014, was performed. The diagnosis of diabetes mellitus established before the KAT was used as the exclusion criterion for participation in the study. As risk factors, gender, age, KAT duration and the use of glucocorticosteroids (GCS), tacrolimus (Tc), and cyclosporin A (CsA) were analyzed; their significance was assessed using stepwise linear regression analysis. Results. The mean age of the recipients at the time of the study was 42.9±20.2 (years. The prevalence of PTDM in the general group was 21.9% (n=32). AGE (P=0.01), the use of CsA and GCSs, the timing of ATP (P=0.01) and the mode of immunosuppressive therapy (P=0.01) had the greatest influence on the development of PTDM. after the conversion of CsA to Tc, the prevalence of PTDM has increased from 11 (18.6%) to 21 (26%) cases. Conclusion. PTDM was diagnosed in 1/5 of the recipients of the kidney transplant. It was revealed that older patients have a greater risk of developing PTDM than younger recipients. Along with age, the use of immunosuppressive therapy with calcineurin inhibitors in combination with GCSs significantly increases the risk of developing PTDM.

Full Text

Restricted Access

About the authors

M. S Novikova

SBHCI "Endocrinological Dispensary of the Moscow Healthcare Department"

Email: citrus7474@mail.ru
PhD in Medical Sciences, Nephrologist

S. S Allazova

FSAEI HE "I.M. Sechenov First Moscow State Medical University" of the Ministry of Health of the Russian Federation

Email: tallisasoto@rambler.ru
Postgraduate Student at the Department of Internal, Occupational Diseases and Rheumatology

O. N Kotenko

SBHCI "City Clinical Hospital № 52 of the Moscow Healthcare Department DZM"; FSAEI HE "Peoples' Friendship University of Russia"

Email: info@gkb52.mosgorzdrav.ru
PhD in Medical Sciences, Chief Freelance Specialist-Nephrologist of the Moscow Healthcare Department, Deputy Chief Physician for Nephrological Care; Associate Professor at the Department of Hospital Therapy with a Course of Hematology

E. M Shilov

FSAEI HE "I.M. Sechenov First Moscow State Medical University" of the Ministry of Health of the Russian Federation

Email: emshilov@mma.ru
Doctor of Medical Sciences, Professor at the Department of Internal, Occupational Diseases and Rheumatology

References

  1. Данович Г.М. Трансплантация почки. Пер. с англ. под ред. Я.Г. Мойсюка. М., 2014. C. 227-260.
  2. Davidson J., Wilkinson A., Dantal J. New-onset diabetes after transplantation 2003. International Consensus Guidelines. Diab. Care. 2004;27(3):805-812.
  3. Ghisdal L., Van Laecke S., Abramowicz M.J., et al. New-onset diabetes after renal transplantation: risk assessment and management. Diab. Care. 2012;35(1):181-188.
  4. Vincenti F., Friman S., Scheuermann E., et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am. J. Transplant. 2007;7(6):1506-1514.
  5. Woodward R.S., Schnitzler M.A., Baty J., et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am. J. Transplant. 2003;3:590-598.
  6. Burroughs T.E., Swindle J., Takemoto S., et al. Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. Transplantation. 2007;83(8):1027-34.
  7. Hjelmesaeth J., Hartmann A., Leivestad T., et al. The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int. 2006;69:588-595.
  8. Kasiske B.L., Snyder J.J., Gilbertson D., Matas A.J. Diabetes mellitus after kidney transplantation in the United States. Am. J. Transplant. 2003; 3(2):178-185.
  9. Дедов И.И., Шестакова М.В., Галстян Г.Р. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом (7-й выпуск). Сахарный диабет. 2015;18(1):7-9.
  10. Cosio F.G., Pesavento T.E., Osei K., et al. Posttransplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int. 2001;59(2):732-737.
  11. Heit J.J., Apelqvist A.A., Gu X., et al. Calcineurin/NFAT signalling regulates pancreatic beta-cell growth and function. Nature. 2006;443:345-349.
  12. Tamura K., Fujimura T., Tsutsumi T., et al. Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell. Transplantation. 1995;59:1606-1613.
  13. Ozbay L.A., Smidt K., Mortensen D.M., et al. Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS-1E ß-cells. Br. J. Pharmacol. 2011;162(1):136-146.
  14. Polastri L., Galbiati F., Bertuzzi F., et al. Secretory defects induced by immunosuppressive agents on human pancreatic beta-cells. Acta Diabetol. 2002;39:229-233.
  15. Duijnhoven E.M., Boots J.M., Christiaans M.H., et al. Influence of tacrolimus on glucose metabolism before and after transplantation: a prospective study. J. Am. Soc. Nephrol. 2001;12:583-588.
  16. Fernandez L.A., Lehmann R., Luzi L., et al. The effects of maintenance doses of FK506 versus Cyclosporin A on glucose and lipid metabolism after orthotopic liver transplantation. Transplantation. 1999;6:1532-1541.
  17. Maffi P., Bertuzzi F., De Taddeo F., et al. Kidney function after islet transplant alone in type 1 diabetes: impact of immunosuppressive therapy on progressive of diabetic nephropathy. Diab. Care. 2007;30:1150-1155.
  18. Neumayer H.H., Farber L., Haller P., et al. Substitution of conventional cyclosporine with a new microemusion formulation in renal transplant patients: result after 1 year. Nephrol. Dial. Transplant. 1996;11:165-172.
  19. Mathew J.T., Rao M., Job V., et al. Post-transplant hyperglycaemia: a study of risk factors. Nephrol. Dial. Transplant. 2003;18:164-171.
  20. Cotovio P., Neves M., Rodrigues L., et al. New-onset diabetes after transplantations: assessment of risk factors and clinical outcomes. Transplant. Proc. 2013;45:1079-1083.
  21. Davidson J.A., Wilkinson A. New-onset diabetes after transplantation 2003 international consensus guidelines: an endocrinologist’s view. Diab. Care. 2004;27:805-812.
  22. Heisel O., Heisel R., Balshaw R., Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am. J. Transplant. 2004;4(4):583-595.
  23. Webster A.C., Woodroffe R.C., Taylor R.S., et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: metaanalysis and meta-regression of randomised trial data. Br. Med. J. 2005; 331(7520):810.
  24. Maes B.D., Kuypers D., Messiaen T., et al. Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: analysis of incidence and risk factors. Transplantation. 2001;72(10):1655-1661.
  25. Ekberg H., Tedesco-Silva H., Demirbas A., et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N. Engl. J. Med. 2007;357(25):2562-2575.
  26. Cai T.H., Esterl R.M., Nichols F., et al. Improved immunosuppression with combination tacrolimus (FK506) and mycophenolic acid in orthotopic liver transplantation. Transplant. Proc. 1998;30(4):1413-1414.
  27. Luan F.L., Zhang H., Schaubel D.E., et al. Comparative risk of impaired glucose metabolism associated with cyclosporine versus tacrolimus in the late posttransplant period. Am. J. Transplant. 2008;8:1871-1877.
  28. Holm A., Hernandez M. A post-hoc analysis of the safety and efficacy of tacrolimus (Prograf) versus a “generic formulation” of tacrolimus (tenacrine) as primary immunosuppressive therapy in LRD and CAD, adults and pediatric renal transplant recipients. Transplantation. 2008;86(2):528.
  29. Meiser B.M., Uberfuhr P., Fuchs A., et al. Single-center randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of acute myocardial rejection. J. Heart Lung Transplant. 1998;17(8):782-788.
  30. Midtvedt K., Hjemesæth J., Hartmann A., et al. Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal. J. Am. Soc. Nephrol. 2004;15(12):3233-3239.
  31. Tillmann F.P., Schmitz M., Rump L.C., Quack I. Impact of low-dose steroids on HbA1c levels and development of pre-diabetes and NODAT in non-diabetic renal transplant recipients on long-termfollow-up. Int. Urol. Nephrol. 2018;50(4):771-777. doi: 10.1007/s11255-017-1754-0.
  32. Luan F.L., Steffick D.E., Ojo A.O. New-onset diabetes mellitus in kidney transplant recipients discharged on steroid-free immunosuppression. Transplantation. 2011;91(3):334-344.
  33. Hjelmesaeth J, Hartmann A, Kofstad J, et al. Tapering off prenisolone and cyclosporine the first year after renal transplantation: the effect on glucose tolerance. Nephrol. Dial. Transplant. 2001;16:829-835.
  34. Hjelmesaeth J., Hartmann A., Kofstad J., et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation. 1997;64(7):979-983.
  35. Knight S.R., Morris P.J. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A Meta-Analysis. Transplantation. 2010;89:1-14.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies